Envestnet Asset Management
CMMB

Envestnet Asset Management’s Chemomab Therapeutics CMMB Stock Holding History

Envestnet Asset Management’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,215
Closed -$41.2K – 3989
2022
Q4 		$41.2K Buy
3,215
+286
+10% +$2.47K ﹤0.01% 3882
2022
Q3 		$29K Sell
2,929
-119
-4% -$1.53K ﹤0.01% 3855
2022
Q2 		$45K Buy
3,048
+346
+13% +$4.82K ﹤0.01% 3827
2022
Q1 		$52K Buy
+2,702
New +$53.3K ﹤0.01% 3854

Other funds holding CMMB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Envestnet Asset Management's CMMB Position: Q1 2023 in Review

Envestnet Asset Management sold out of Chemomab Therapeutics (CMMB) in Q1 2023, closing a stake of 3,215 shares — an estimated $41.2K sold.

Envestnet Asset Management first reported a position in CMMB in Q1 2022 and held it in 4 quarters. The position peaked at $52K in Q1 2022. 14 funds tracked by Wall St. Rank hold CMMB as of Q1 2023.

  • Envestnet Asset Management reported no remaining Chemomab Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Envestnet Asset Management sold 3,215 Chemomab Therapeutics shares in Q1 2023, an estimated $41.2K.
  • Envestnet Asset Management first reported a position in Chemomab Therapeutics in Q1 2022 and held it in 4 quarters.
  • Envestnet Asset Management's Chemomab Therapeutics position peaked at $52K in Q1 2022.
  • 14 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q1 2023.

Based on Envestnet Asset Management's 13F filing for Q1 2023, filed 11 May 2023.